August 15, 2023 – BackStop Neural is thrilled to announce the appointment of Dr. Steven Falowski to its Advisory Board as the company continues to advance its innovative neurostimulation technology. Dr. Falowski is an award-winning neurosurgeon, renowned for his expertise and leadership in the field of neurosurgery and especially neuromodulation. With this strategic addition, BackStop Neural amplifies its commitment to pioneering cutting-edge solutions that transform the lives of patients suffering from chronic pain and paralysis.
Dr. Falowski has an impressive track record of achievements and has earned recognition for his contributions to medical research and patient care, including winning the research award at the PAN Philadelphia Neurosurgical Conference for his work dealing with DBS in a depression model. He completed his residency at Thomas Jefferson University in Philadelphia, a functional neurosurgical fellowship at Rush University in Chicago, sits on the boards of the International Neuromodulation Society (INS) and the American Society of Pain and Neuroscience (ASPN), and is director of functional neurosurgery at Neurosurgical Associates of Lancaster. Dr. Falowski also sits as education director for multiple societies ensuring the growth and proper training of physicians in the space. His expertise in the field and dedication to enhancing patient outcomes align perfectly with BackStop Neural's vision of improving lives through innovation.
As a trailblazing spinal cord stimulator company, BackStop Neural is leveraging proprietary chemistry and cutting-edge semiconductor manufacturing processes to produce softening thin-film spinal cord stimulator electrodes that conform to the spinal cord and are ten times thinner than current products. Through their innovative neuromodulation devices, the company seeks to unlock spinal cord stimulation for pain relief and motor recovery in the neck and upper limbs. Dr. Falowski's invaluable insights and experience will be instrumental in guiding BackStop Neural as it continues to push the boundaries of neuromodulation technology.
"I am honored to join BackStop Neural's Advisory Board," stated Dr. Falowski. "The company's thin-film spinal cord stimulation technology has the potential to fulfill an unmet need that unlocks the benefits of spinal cord stimulation for patients suffering from chronic pain in the neck and upper limbs. I am excited to contribute my expertise and collaborate with this exceptional team to bring about positive change in the lives of those suffering from chronic pain and neurological disorders."
In his new capacity as an Advisory Board member, Dr. Falowski will actively collaborate with BackStop Neural's leadership team, providing expert guidance on product development, clinical trials, and overall strategy. His presence on the Advisory Board will be integral to fostering relationships with key stakeholders, including medical professionals, researchers, and regulatory bodies, ultimately advancing BackStop Neural's mission to improve millions of lives.
"We are delighted to welcome Dr. Falowski to our esteemed Advisory Board," said Kial Gramley, Chief Product Officer of BackStop Neural. "His wealth of knowledge and vast experience in neurosurgery and neuromodulation will be instrumental in guiding our team towards the development of groundbreaking spinal cord stimulation technologies. With Dr. Falowski's guidance, we are confident in our ability to revolutionize patient care and give relief to those suffering from chronic pain."
About BackStop Neural
BackStop Neural is a pioneering medical device company that specializes in developing advanced spinal cord stimulation solutions for individuals suffering from chronic pain. Through proprietary materials and neurostimulation technology, the company strives to provide patients with a renewed sense of hope and freedom from debilitating conditions. With a team of dedicated experts and a patient-centered approach, BackStop Neural aims to transform the landscape of neurology and elevate the standard of patient care.
For media inquiries, please contact:
Kial Gramley, Chief Product Officer